16 October 2024

India | Equity Research | Q2FY25 results review

Newgen Software Technologies

Technology

Strong show, yet again!

Newgen reported strong revenue growth of 23.2% YoY in Q2FY25 led by license sales predominantly in APAC and healthy growth across other markets. We built in 24%/25% revenue/EPS CAGR over FY24-27E. We now value Newgen at 50x (earlier 40x) led by 1) improved growth visibility on continued traction in banking in India and EMEA markets, focus on building scale in health insurance and government segments, healthy orderbook (22% YoY in H1FY25), with growing deal sizes, 2) strong client-mining ability – INR 50mn+ client bucket grew 2.5x to 65 in 3 years, 3) potential revenue upside when US engine fires up and 4) steady EBITDA margin above 23%. We value the stock at 50x P/E on Q2FY26-Q1FY27E EPS of INR 25 to arrive at revised TP of INR 1,260. Maintain **HOLD** on stretched valuations.

Sustained strong revenue growth momentum

Newgen reported strong revenue growth of 23.2% YoY led by license sales (56% YoY) predominantly in APAC (53% YoY) and healthy growth across other markets – EMEA (21.3% YoY), India (18.9% YoY) and US (16.7% YoY). Annuity revenue growth slowed down to 14% YoY due to slowdown in ATS revenue on account of longer implementation cycles of recently won large deals. ATS revenue could pick up once execution of these deals is complete. SaaS revenue growth (12.4% YoY) is lower due to softer new logo addition in the US.

Focusing on scaling health-insurance and government segments

Newgen is now focusing on scaling up health-insurance and government segments and not just depending on banking (~72% of revenue) for growth. It launched accelerators to fit each market in health-insurance segment. Newgen won two large deals -1) TCV of INR 0.25bn from a large insurance company in India for building its system of engagement and 2) from one Middle East client. Pipeline is healthy and management expects to convert more deals in this segment in H2. In government segment, deal pipeline is good in Singapore, Saudi, Kuwait and to some extent in India.

Continued traction in banking in India and EMEA

Demand momentum in banking continues to be strong in EMEA. In India, captive finance and trade finance solutions are gaining traction. There is demand across lending, trade finance, captive finance and supply-chain finance.

Financial Summary

| Y/E March (INR mn) | FY24A | FY25E | FY26E | FY27E |
|--------------------|--------|--------|--------|--------|
| Net Revenue | 12,438 | 15,655 | 19,348 | 23,563 |
| EBITDA | 2,890 | 3,779 | 4,527 | 5,498 |
| EBITDA Margin (%) | 23.2 | 24.1 | 23.4 | 23.3 |
| Net Profit | 2,516 | 3,256 | 3,918 | 4,959 |
| EPS (INR) | 18.0 | 23.3 | 28.0 | 35.5 |
| EPS % Chg YoY | 43.2 | 29.1 | 20.4 | 26.6 |
| P/E (x) | 71.9 | 55.7 | 46.3 | 36.5 |
| EV/EBITDA (x) | 61.0 | 46.3 | 38.1 | 30.9 |
| RoCE (%) | 20.1 | 21.0 | 20.9 | 21.2 |
| RoE (%) | 23.4 | 25.1 | 24.9 | 25.9 |

Ruchi Mukhija

ruchi.mukhija@icicisecurities.com 22 6807 7573

Aditi Patil

aditi.patil@icicisecurities.com

Seema Nayak

seema.nayak@icicisecurities.com

Market Data

| Market Cap (INR) | 182bn |
|---------------------|------------|
| Market Cap (USD) | 2,165mn |
| Bloomberg Code | NEWGEN IN |
| Reuters Code | NEWG BO |
| 52-week Range (INR) | 1,548 /459 |
| Free Float (%) | 45.0 |
| ADTV-3M (mn) (USD) | 5.3 |

| Price Performance (%) | 3m | 6m | 12m |
|-----------------------|------|------|-------|
| Absolute | 24.8 | 72.3 | 184.0 |
| Relative to Sensex | 23.3 | 60.9 | 1606 |

| Earnings Revisions (%) | FY25E | FY26E | FY27E |
|---------------------------|-------|-------|-------|
| Revenue | 0.0 | 0.0 | 0.0 |
| EBITDA | 3.0 | 0.0 | 0.0 |
| EPS | 3.0 | 0.0 | 0.0 |

Previous Reports

19-07-2024: <u>Q1FY25 results review</u> 17-01-2024: <u>Q3FY24 results review</u>



Healthy orderbook momentum and pipeline

Orderbook has grown strongly at 22% YoY in H1FY25. Pipeline in traditional market is growing at a healthy pace; financial services' revenues are getting diversified across solutions. Pipeline is also building up in health-insurance and government segments (across markets) and in US market.

Management expects deal velocity to improve in US in H2FY25. It won a large deal of TCV USD 1.5mn to provide Enterprise Content Management Solution to one of the top financial institutions in the US in Q2FY25.

Higher license sales lifted margins

EBITDA margin improved sharply by 350bps YoY to 23% largely driven by higher proportion of high-margin product license revenue. R&D expense was 9% and sales and marketing was 22% of sales. The company aims to maintain EBITDA margin at 23%+ and invest in marketing activities to create larger sales funnel.

Launched several new solutions and product versions

Newgen launched new solutions and product versions in Q2FY25 including: 1) Islamic retail lending, 2) captive finance management, 3) enhanced video KYC, 4) new version of content management platform and new version of Newgen Marvin (Al platform).

Key downside risks: 1) High competition, particularly with large consolidated players, 2) adverse macros in key markets of India and EMEA. **Key upside risks**: 1) Continued strong macro tailwinds in India and EMEA, 2) earlier-than-expected recovery in US market.

Exhibit 1: Strong show in Q2FY25

| INR mn | Q2FY25 | Q1FY25 | QoQ | Q2FY24 | YoY |
|---------------|--------|--------|---------|--------|---------|
| Sales | 3,612 | 3,147 | 14.8% | 2,932 | 23.2% |
| EBITDA | 830 | 477 | 74.2% | 572 | 45.0% |
| EBITDA Margin | 23.0% | 15.1% | 784 bps | 19.5% | 346 bps |
| PBT | 926 | 615 | 50.6% | 586 | 58.0% |
| Tax | 222 | 139 | 59.8% | 108 | 105.6% |
| Tax Rate | 24.0% | 22.6% | 138 bps | 18.5% | 557 bps |
| Reported PAT | 703 | 476 | 47.9% | 478 | 47.2% |
| EPS | 4.9 | 3.3 | 47.6% | 3.4 | 42.8% |

Source: I-Sec research, Company data

Exhibit 2: Change in estimates

| | Revised | | | | Previous | | Change | | |
|-------------------------|---------|--------|--------|--------|----------|--------|--------|-------|-------|
| INR mn | FY25E | FY26E | FY27E | FY25E | FY26E | FY27E | FY25E | FY26E | FY27E |
| Revenues | 15,655 | 19,348 | 23,563 | 15,681 | 19,388 | 23,612 | 0% | 0% | 0% |
| EBITDA | 3,779 | 4,527 | 5,498 | 3,660 | 4,536 | 5,509 | 3% | 0% | 0% |
| EBITDA margin | 24.1 | 23.4 | 23.3 | 23.3 | 23.4 | 23.3 | 80bps | 0bps | 0bps |
| Diluted EPS (INR/share) | 22.6 | 27.1 | 34.3 | 22.0 | 27.2 | 34.4 | 3% | 0% | 0% |

Source: I-Sec research, Company data

Exhibit 3: Growth driven by health-insurance and BFSI segments

| Vertical revenue growth YoY | Q1FY22 | Q2FY22 | Q3FY22 | Q4FY22 | Q1FY23 | Q2FY23 | Q3FY23 | Q4FY23 | Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 |
|-----------------------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| Banking and Financial Services | 44.9% | 41.4% | 5.8% | 24.0% | 10.6% | 16.3% | 33.9% | 39.7% | 44.7% | 54.8% | 23.2% | 26.5% | 34.4% | 19.8% |
| Government/ PSUs | 20.8% | -40.2% | 20.1% | 13.8% | 51.4% | 357.1% | -8.5% | -20.9% | 4.2% | -30.8% | 74.6% | 2.5% | -10.7% | 5.8% |
| Healthcare + Insurance | 4.7% | 0.8% | 1.4% | 26.3% | 45.0% | -1.0% | 54.9% | 41.2% | 8.8% | 9.7% | 34.9% | 6.6% | 44.3% | 67.9% |
| Others | -26.5% | -0.3% | 29.0% | -28.0% | 9.4% | -18.7% | -12.9% | 17.2% | 33.9% | -9.2% | -1.2% | 38.4% | -23.0% | 7.8% |
| Total | 20.8% | 19.7% | 9.2% | 15.7% | 17.8% | 21.9% | 25.9% | 31.8% | 33.9% | 29.7% | 27.0% | 23.0% | 25.0% | 23.2% |

Source: I-Sec research, Company data



Exhibit 4: Broad-based growth across geographies

| Geo revenue growth YoY | Q1FY22 | Q2FY22 | Q3FY22 | Q4FY22 | Q1FY23 | Q2FY23 | Q3FY23 | Q4FY23 | Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 |
|------------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| India | 4.6% | 13.6% | 2.2% | 14.4% | 67.3% | 27.2% | 39.9% | 37.9% | 24.5% | 37.9% | 29.3% | 38.9% | 19.7% | 18.9% |
| EMEA | 57.0% | 58.7% | 20.2% | 41.0% | 22.9% | 23.8% | 26.9% | 33.8% | 38.4% | 34.4% | 41.4% | 42.3% | 25.0% | 21.3% |
| APAC | 45.2% | 3.2% | 25.8% | 8.8% | 12.5% | 39.1% | 18.1% | 4.2% | 45.7% | 2.2% | 17.8% | 7.1% | 64.9% | 52.9% |
| US | 4.8% | 2.7% | 0.1% | -4.4% | -17.8% | 5.4% | 13.4% | 39.9% | 35.8% | 29.9% | 12.6% | -15.0% | 12.9% | 16.7% |
| Total | 20.8% | 19.7% | 9.2% | 15.7% | 17.8% | 21.9% | 25.9% | 31.8% | 33.9% | 29.7% | 27.0% | 23.0% | 25.0% | 23.2% |

Source: I-Sec research, Company data

Exhibit 5: Revenue growth driven by sale of licenses and services (implementation)


| Service line revenue growth YoY | Q1FY22 | Q2FY22 | Q3FY22 | Q4FY22 | Q1FY23 | Q2FY23 | Q3FY23 | Q4FY23 | Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 |
|---------------------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| Sale of products – softwares | 28.3% | 54.9% | 36.5% | -16.6% | -44.6% | 16.4% | 15.8% | 39.1% | 184.6% | 5.0% | -6.2% | 29.5% | 3.0% | 55.7% |
| Annuity based revenue | | | | | | | | | | | | | | |
| AMC/ATS | 7.8% | 19.7% | 19.6% | 52.8% | 31.9% | 27.0% | 20.4% | 8.9% | 14.8% | 8.9% | 9.7% | 16.5% | 9.4% | 12.2% |
| Support | 28.8% | 11.9% | 5.0% | 6.0% | 17.8% | 17.7% | 35.9% | 42.8% | 29.8% | 38.9% | 36.4% | 37.2% | 29.1% | 16.0% |
| SaaS Revenue | 35.8% | 34.6% | 9.2% | 66.4% | 30.9% | 35.4% | 97.8% | 64.8% | 47.3% | 29.7% | 27.0% | 10.7% | 25.0% | 12.4% |
| Sale of services | 14.0% | -4.3% | -16.0% | 20.9% | 52.4% | 21.9% | 7.0% | 26.9% | 3.5% | 78.3% | 79.2% | 13.6% | 61.8% | 23.2% |
| Total | 20.8% | 19.7% | 9.2% | 15.7% | 17.8% | 21.9% | 25.9% | 31.8% | 33.9% | 29.7% | 27.0% | 23.0% | 25.0% | 23.2% |

Source: I-Sec research, Company data

Exhibit 6: Shareholding pattern

| % | Mar'24 | Jun'24 | Sep'24 |
|-------------------------|--------|--------|--------|
| Promoters | 55.0 | 54.3 | 54.3 |
| Institutional investors | 26.1 | 27.9 | 29.2 |
| MFs and others | 3.7 | 3.9 | 3.1 |
| Fls/Banks | 0.0 | 0.0 | 5.9 |
| Insurance | 0.2 | 0.2 | 0.2 |
| FIIs | 22.2 | 23.8 | 20.0 |
| Others | 18.9 | 17.8 | 16.5 |

Exhibit 7: Price chart



Source: Bloomberg Source: Bloomberg



Financial Summary

Exhibit 8: Profit & Loss

(INR mn, year ending March)

| | FY24A | FY25E | FY26E | FY27E |
|-----------------------------|---------|---------|---------|---------|
| Net Sales (US\$ mn) | 150 | 189 | 233 | 284 |
| Net Sales (Rs. mn) | 12,438 | 15,655 | 19,348 | 23,563 |
| Operating Expense | 9,549 | 11,876 | 14,821 | 18,065 |
| EBITDA | 2,890 | 3,779 | 4,527 | 5,498 |
| EBITDA Margin (%) | 2,323.1 | 2,413.8 | 2,339.6 | 2,333.3 |
| Depreciation & Amortization | 280 | 344 | 457 | 495 |
| EBIT | 2,610 | 3,435 | 4,070 | 5,003 |
| Interest expenditure | - | - | - | - |
| Other Non-operating Income | 432 | 670 | 767 | 1,119 |
| Recurring PBT | 3,042 | 4,105 | 4,837 | 6,122 |
| Profit / (Loss) from | | | | |
| Associates | - | - | - | - |
| Less: Taxes | 527 | 849 | 919 | 1,163 |
| PAT | 2,516 | 3,256 | 3,918 | 4,959 |
| Less: Minority Interest | - | - | - | - |
| Net Income (Reported) | 2,516 | 3,256 | 3,918 | 4,959 |
| Extraordinaries (Net) | - | - | - | - |
| Recurring Net Income | 2,516 | 3,256 | 3,918 | 4,959 |

Source Company data, I-Sec research

Exhibit 9: Balance sheet

(INR mn, year ending March)

| · | | | | |
|-----------------------------|--------|--------|--------|--------|
| | FY24A | FY25E | FY26E | FY27E |
| Total Current Assets | 9,301 | 12,278 | 15,941 | 20,351 |
| of which cash & cash eqv. | 3,364 | 5,063 | 7,259 | 9,995 |
| Total Current Liabilities & | 3,083 | 3,382 | 3,738 | 4,096 |
| Provisions | 3,063 | 3,302 | 3,730 | 4,090 |
| Net Current Assets | 6,218 | 8,896 | 12,203 | 16,255 |
| Investments | 1,314 | 1,314 | 1,314 | 1,314 |
| Net Fixed Assets | 1,555 | 1,445 | 1,279 | 1,137 |
| ROU Assets | 638 | 638 | 638 | 638 |
| Capital Work-in-Progress | - | - | - | - |
| Goodwill | - | - | - | - |
| Other assets | 2,336 | 2,336 | 2,336 | 2,336 |
| Deferred Tax Assets | 184 | 184 | 184 | 184 |
| Total Assets | 12,574 | 15,187 | 18,378 | 22,346 |
| Liabilities | | | | |
| Borrowings | 20 | 20 | 20 | 20 |
| Deferred Tax Liability | 33 | 33 | 33 | 33 |
| provisions | 409 | 515 | 689 | 839 |
| other Liabilities | 407 | 407 | 407 | 407 |
| Minority Interest | - | - | - | - |
| Equity Share Capital | 11,705 | 14,212 | 17,229 | 21,047 |
| Reserves & Surplus* | - | - | - | - |
| Total Net Worth | 11,705 | 14,212 | 17,229 | 21,047 |
| Total Liabilities | 12,574 | 15,187 | 18,378 | 22,346 |

Source Company data, I-Sec research

Exhibit 10: Quarterly trend

(INR mn, year ending March)

| | Dec-23 | Mar-24 | Jun-24 | Sep-24 |
|---------------------|--------|--------|--------|--------|
| Net Sales | 3,237 | 3,753 | 3,147 | 3,612 |
| % growth (YOY) | 27.0 | 23.0 | 25.0 | 23.2 |
| EBITDA | 770 | 1,226 | 477 | 830 |
| Margin % | 23.8 | 32.7 | 15.1 | 23.0 |
| Other Income | 112 | 151 | 226 | 185 |
| Adjusted Net Profit | 683 | 1,053 | 476 | 703 |

Source Company data, I-Sec research

Exhibit 11: Cashflow statement

(INR mn, year ending March)

| | FY24A | FY25E | FY26E | FY27E |
|--|-------|-------|-------|---------|
| CFO before WC changes | 2,890 | 3,779 | 4,527 | 5,498 |
| CFO after WC changes | 2,140 | 2,861 | 3,540 | 4,274 |
| Capital Commitments | (187) | (235) | (290) | (353) |
| Free Cashflow | 1,800 | 2,247 | 2,911 | 3,464 |
| Other investing cashflow | 481 | 711 | 810 | 1,161 |
| Cashflow from Investing Activities | 294 | 476 | 520 | 808 |
| Issue of Share Capital | - | - | - | - |
| Interest Cost | - | - | - | - |
| Inc (Dec) in Borrowings | - | - | - | - |
| Cash flow from Financing Activities | (627) | (790) | (944) | (1,183) |
| Dividend paid | (579) | (749) | (901) | (1,140) |
| Others | (48) | (41) | (43) | (43) |
| Chg. in Cash & Bank balance | 1,280 | 1,699 | 2,197 | 2,735 |
| Closing cash & balance | 3,364 | 5,063 | 7,259 | 9,995 |

Source Company data, I-Sec research

Exhibit 12: Key ratios

(Year ending March)

| . 3 , | <u> </u> | | | <u> </u> |
|----------------------------------|----------|--------|--------|----------|
| | FY24A | FY25E | FY26E | FY27E |
| Per Share Data (INR) | | | | |
| Reported EPS | 18.0 | 23.3 | 28.0 | 35.5 |
| Diluted EPS | 17.4 | 22.6 | 27.1 | 34.3 |
| Cash EPS | 20.0 | 25.7 | 31.3 | 39.0 |
| Dividend per share (DPS) | 4.1 | 5.4 | 6.4 | 8.2 |
| Book Value per share (BV) | 83.9 | 101.6 | 123.2 | 150.5 |
| Dividend Payout (%) | 23.8 | 23.7 | 23.8 | 23.8 |
| Growth (%) | | | | |
| Net Sales | 27.7 | 25.9 | 23.6 | 21.8 |
| EBITDA | 36.2 | 30.8 | 19.8 | 21.5 |
| EPS | 43.2 | 29.1 | 20.4 | 26.6 |
| Valuation Ratios (x) | | | | |
| P/E | 71.9 | 55.7 | 46.3 | 36.5 |
| P/CEPS | 64.7 | 50.3 | 41.4 | 33.2 |
| P/BV | 15.4 | 12.8 | 10.5 | 8.6 |
| EV / EBITDA | 61.0 | 46.3 | 38.1 | 30.9 |
| P/S | 14.5 | 11.6 | 9.4 | 7.7 |
| Dividend Yield (%) | 0.3 | 0.4 | 0.5 | 0.6 |
| Operating Ratios | | | | |
| EBITDA Margins (%) | 23.2 | 24.1 | 23.4 | 23.3 |
| EBIT Margins (%) | 21.0 | 21.9 | 21.0 | 21.2 |
| Effective Tax Rate (%) | 17.3 | 20.7 | 19.0 | 19.0 |
| Net Profit Margins (%) | 20.2 | 20.8 | 20.3 | 21.0 |
| Inventory Turnover Days | _ | _ | _ | _ |
| Fixed Asset Turnover (x) | 7.8 | 10.4 | 14.2 | 19.5 |
| Receivables Days | 129 | 130 | 131 | 132 |
| Payables Days | 12 | 12 | 12 | 12 |
| Working Capital Days | 72 | 78 | 83 | 87 |
| Net Debt / EBITDA (x) | (16.7) | (18.5) | (18.7) | (22.8) |
| Profitability Ratios | | | | |
| RoCE (%) | 20.1 | 21.0 | 20.9 | 21.2 |
| RoIC (%) | 47.2 | 50.1 | 51.7 | 53.6 |
| RoNW (%) | 23.4 | 25.1 | 24.9 | 25.9 |
| Source Company data, I-Sec resea | ırch | | | |

Source Company data, I-Sec research



This report may be distributed in Singapore by ICICI Securities, Inc. (Singapore branch). Any recipients of this report in Singapore should contact ICICI Securities, Inc. (Singapore branch) in respect of any matters arising from, or in connection with, this report. The contact details of ICICI Securities, Inc. (Singapore branch) are as follows: Address: 10 Collyer Quay, #40-92 Ocean Financial Tower, Singapore - 049315, Tel: +65 6232 2451 and email: navneet_babbar@icicisecuritiesinc.com, Rishi garawal@icicisecuritiesinc.com.

"In case of eligible investors based in Japan, charges for brokerage services on execution of transactions do not in substance constitute charge for research reports and no charges are levied for providing research reports to such investors."

New I-Sec investment ratings (all ratings based on absolute return; All ratings and target price refers to 12-month performance horizon, unless mentioned otherwise) BUY: >15% return; ADD: 5% to 15% return; HOLD: Negative 5% to Positive 5% return; REDUCE: Negative 5% to Negative 15% return; SELL: < negative 15% return

ANALYST CERTIFICATION

I/We, Ruchi Mukhija, CA; Aditi Patil, MBA; Seema Nayak, MBA; authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of the ICICI Securities Inc. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. Registered Office Address: ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025. CIN: L67120MH1995PLC086241, Tel: (91 22) 6807 7100. ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager, Research Analyst and Alternative Investment Fund. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number - INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities AIF Trust's SEBI Registration number is IN/AIF3/23-24/1292 ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Institutional Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Retail Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances. This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.
ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been managed by the subject

company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/beneficial ownership of one percent or more or other material conflict of interest in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

. This report has not been prepared by ICICI Securities, Inc. However, ICICI Securities, Inc. has reviewed the report and, in so far as it includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.



Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk free return to the investors.

 $Name of the Compliance of ficer (Research Analyst): Mr. Atul Agrawal, Contact number: 022-40701000, \ \textbf{E-mail Address}: \underline{compliance of ficer@icicisecurities.com}$

For any queries or grievances: Mr. Bhavesh Soni Email address: headservicequality@icicidirect.com Contact Number: 18601231122